Wuhan Createrna Science and Technology Co., Ltd
12
3
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
25%
3 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Role: lead
Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Role: lead
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Role: lead
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
Role: lead
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Role: lead
QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study
Role: lead
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
Role: lead
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Role: lead
To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects
Role: lead
A Study of Single-dose MY008211A in Healthy Adults
Role: lead
A Study of Multiple Ascending Doses MY008211A in Healthy Adults
Role: lead
Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects
Role: lead
All 12 trials loaded